MedTrace Logo

Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy

NCT00056238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-06-24

No results posted yet for this study

Summary

The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.

Conditions

  • Stroke
  • Neurologic Diseases, General

Interventions

DRUG

NC-758 (Anti amyloidotic [Aß] agent)

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Principal Investigators

  • Steven M. Greenberg, M.D., PhD. · Massachusetts General Hospital

  • Co-sponsor: National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056238 on ClinicalTrials.gov